AD35-vectored immunogenic composition for SARS-COV-2 infection
US12128097B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Feb 2, 2021 |
| Grant date | Oct 29, 2024 |
| Priority date | — |
| Expiry date | Nov 22, 2042 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2770/20034
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a replication-defective Ad35-vectored immunogenic composition for inducing immune response against SARS COV-2, comprising an Ad35 vector, wherein the Ad35 vector encodes the optimized nucleic acid sequence of SEQ ID NO: 1. Some embodiments of the present disclosure have better safety and use convenience. Experiments have shown that the immunogenic composition can produce more S proteins in human cells. Some embodiments of the present disclosure may be used in combination with another immunogenic composition or may also be used as a therapeutic immunogenic composition for Corona Virus Disease 2019. When a patient is immunized with the Ad35-vectored immunogenic composition of the present disclosure at the initial stage of infection, the immunogenic composition induces an immune response in the human body, thereby achieving a therapeutic effect.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.